2013
DOI: 10.1093/cid/cit560
|View full text |Cite
|
Sign up to set email alerts
|

The Empirical Combination of Vancomycin and a  -Lactam for Staphylococcal Bacteremia

Abstract: The high prevalence of methicillin resistance among Staphylococcus aureus bacteremias leads to common use of vancomycin as empirical therapy. However, investigators have reported poor outcomes with vancomycin treatment for methicillin-susceptible Staphylococcus aureus bacteremia. We review the evidence supporting empirical combination of both vancomycin and a β-lactam agent for Staphylococcus aureus bacteremia. Vancomycin therapy for methicillin-susceptible Staphylococcus aureus bacteremia is associated with 2… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
53
0
1

Year Published

2014
2014
2020
2020

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 74 publications
(56 citation statements)
references
References 47 publications
2
53
0
1
Order By: Relevance
“…An analysis of the literature, however, compared the use of empirical combination of vancomycin and antistaphylococcal β-lactam therapy with vancomycin alone and demonstrated the superiority of β-lactam-containing regimens over vancomycin monotherapy for bacteremic MSSA infections, including IE. 153 This differential outcome included studies in which there was an early shift from empirical vancomycin to β-lactam therapy as soon as blood cultures yielded MSSA (not MRSA). The meta-analysis included small, retrospective studies, however, which limits support for initial combination therapy by some experts.…”
Section: Ie In Non-idusmentioning
confidence: 99%
“…An analysis of the literature, however, compared the use of empirical combination of vancomycin and antistaphylococcal β-lactam therapy with vancomycin alone and demonstrated the superiority of β-lactam-containing regimens over vancomycin monotherapy for bacteremic MSSA infections, including IE. 153 This differential outcome included studies in which there was an early shift from empirical vancomycin to β-lactam therapy as soon as blood cultures yielded MSSA (not MRSA). The meta-analysis included small, retrospective studies, however, which limits support for initial combination therapy by some experts.…”
Section: Ie In Non-idusmentioning
confidence: 99%
“…In patients with methicillinsusceptible S aureus (MSSA) or group A streptococcal (GAS) infection, a change from either vancomycin or clindamycin to a β-lactam agent would be considered appropriate, based on clinical data and expert opinion. [14][15][16][17][18] Furthermore, vancomycin cannot be continued at our institution beyond 48 hours when alternative antibiotics are effective without approval of the antibiotic stewardship program. Antibiotic pretreatment was regarded as ≥1 dose of intravenous antibiotics administered ≥1 h before the obtainment of operating room (OR) or IR-guided cultures.…”
Section: Defi Nitionsmentioning
confidence: 99%
“…Although a negative PBP2a result is not currently reported by our laboratory, consideration is given to continuation of a combination of vancomycin and a relevant anti-staphylococcal penicillin (oxacillin and nafcillin) or cephalosporin, as vancomycin single therapy still appears inferior to initial b-lactam therapy for MSSA (McConeghy et al, 2013;Mongkolrattanothai et al, 2009). If a positive result is obtained, de-escalation to vancomycin as a single agent is warranted.…”
Section: Discussionmentioning
confidence: 90%
“…There may be clinical benefit demonstrated in such randomized control studies as the treatment of a MSSA with vancomycin alone is clearly associated with a more complicated disease prognosis (McConeghy et al, 2013;Mongkolrattanothai et al, 2009). If such an approach is adopted, the SIMI/CCT may be of benefit for either discontinuing the b-lactam with a positive result or discontinuing vancomycin in the case of a negative result.…”
Section: Discussionmentioning
confidence: 99%